Sign up for our complimentary
weekly e-journal

 
Bookmark and Share | Print | Category | Home Previous | All Articles This Week | Next
This article originally posted 14 December, 2003 and appeared in  Issue 185

Renal Disease Progresses in Slowly Type 2 Diabetics

Renal Disease Progresses in Slowly Type 2 Diabetics Type 2 diabetic patients without overt nephropathy have a significant, but slow, course of renal insufficiency.
Advertisement
New Page 1
Renal Disease Progresses in Slowly Type 2 Diabetics

Type 2 diabetic patients without overt nephropathy have a significant, but slow, course of renal insufficiency.

"In patients with type 2 diabetes with overt nephropathy, the risk for progressive renal failure is high," Dr. Johannes F. E. Mann, of Schwabing General Hospital, Munchen, German, and colleagues write. "The risk is less well established for those with type 2 diabetes and microalbuminuria or normalbuminuria."

The researchers examined changes in serum creatinine levels in 3577 diabetic patients at high cardiovascular risk with microalbuminuria or normalbuminuria. They conducted a retrospective analysis of serum creatinine levels at baseline and every year thereafter in the Microalbuminuria and Renal Outcomes in the Heart Outcomes and Prevention Evaluation study comparing the effects of ramipril and placebo during 4.5 years. Included were 1139 patients with microalbuminuria and 333 with normalbuminuria.

No significant increases in serum creatinine levels were observed during the study when all diabetic subjects were considered or for subgroups with microalbuminuria and/or renal insufficiency at baseline. There were no differences between patients treated with ramipril and those who received placebo.

Of 3238 people, 474 newly developed a serum creatinine level of 1.4 mg/dL or greater, including 243 placebo-treated patients and 231 ramipril-treated patients, a difference between the groups that was not statistically significant. Of the 333 patients with baseline renal insufficiency, 8 saw their serum creatinine levels double or developed end-stage renal disease.

"On the basis of reaching threshold levels of renal function, progression rates are clinically meaningful, especially considering population life expectancy," the authors conclude. Am J Kidney Dis 2003;42:936-942.

================================

Cholestech GDX™ A1C Testing System With Instant Results
CLIA-waived - A1C results in 5 minutes - Increased office revenue– NGSP-certified – Reimbursable.
Find out More!

A new Thyroid Test for Home use is now available. More Info

The 10,000 STEP STUDY: “The Results” A simple answer to a difficult problem. CLICK HERE
 

Bookmark and Share | Print | Category | Home

This article originally posted 14 December, 2003 and appeared in  Issue 185

Past five issues: Issue 537 | Issue 536 | Issue 535 | Issue 534 | Issue 533 |

Diabetes In Control Advertisers
Cast Your Vote
What percent of your Type 2 patients are on oral triple therapy and have an A1c below 6.4%?
Featured Jobs
CME/CE of the Week
Category: Nutrition
CE Credits: .75
 

Free Weekly Newsletter
Sign up here.

Free CE Available
CE Programs on diabetes

Sponsored Link


Advertisement


Advertisement




Search Articles On Diabetes In Control